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Metallothioneins are a group of low-molecular-weight intracellular proteins present in high levels in fetal mammalian livers, bound to zinc and cop-
per. They are also present in two major isoforms in low basal levels in various organs of adults in several species. Although a number of functions
have been proposed for metallothioneins, their major biological roles may be in the storage of zinc and copper during rapid growth and develop-
ment, and also in the detoxification of certain toxic metals. In adult liver, metallothionein is mainly localized in the cytoplasm, it is localized also in the
hepatocyte nuclei in human fetal liver and fetal and neonatal rat liver, as determined by immunohistochemical staining with a specific metalloth-
ionein antibody. Because of its high expression in fetal development, the potential role of metallothioneins in human tumors was investigated. The
cellular localization of metallothionein was demonstrated in various human tumors such as thyroid tumors, testicular germ cell carcinoma, bladder
transitional cell carcinomas, and salivary gland tumors. In most of these tumor tissues, metallothioneins were found in high levels in nucleus and
cytoplasm in both benign and malignant tumors, although the proliferating edge of the malignant tumors showed most intense metallothionein
staining. The expression of metallothionein is not universal to all tumor growth; its presence may depend on various factors, such as the type of
tumor, cellular origin, morphological heterogeneity, or stage of growth. Human testicular seminomas, which are well differentiated, showed little
expression of metallothionein irrespective of the staging, as compared to less well-differentiated embryonal carcinomas. Preliminary studies with
DNA flow cytometry on adenocarcinoma of breast and colon, using a fluorescent antibody to metallothionein, showed that metallothionein was pre-
sent in the nucleus of the epithelial cells only in the S-phase of the cell cycle. Thus the nuclear presence of metallothionein in tumor cells is indica-
tive of their proliferative activity, and metallothionein staining may be used as a marker of the proliferation index of certain tumors. - Environ Health
Perspect 102(Suppl 3):131-135 (1994).
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Introduction
The cellular requirement of essential met-
als, their homeostatic control, and bio-
logical and toxicological effects are
controlled by a number of specific metal-
binding proteins. These metalloproteins are
involved in the storage, transport, and bio-
logical properties of many metals.
Therefore it is important to study the type
of binding of metals to proteins and their
intracellular localization to understand the
biological functions and mechanisms of
action of metals. The role of proteins such
as ceruloplasmin, transferrin, and ferritin in
the metabolism of copper and iron is
extensively studied in various laboratories
(1-5). Because of their high affinity for
metals, metallothioneins may play a physi-
ologic role in the absorption, storage, and
metabolism of important trace metals such
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as zinc and copper, as well as in detoxifica-
tion of certain toxic metals such as cad-
mium and mercury. This brief review will
focus on some of the recent work in our
laboratory on the changes in intracellular
localization ofmetallothioneins in the liver
during mammalian development and on its
expression in certain human tumors.
Although metallothionein was first iso-
lated and characterized as a cadmium-bind-
ing protein from horse kidney (6), several
studies (7-9) showed its presence in many
tissues as a zinc-and copper-binding pro-
tein. Most adult mammalian tissues con-
tain low basal levels of metallothioneins
which may vary with age and type of tis-
sues. The presence of high levels of intra-
cellular metallothionein during gestation
and the early postnatal period, bound to
zinc and copper in mammalian liver, is well
documented (7-11). The estimation of
metallothionein and metals in human liver
and kidney for different age groups showed
(12) high levels of zinc and copper bound
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Figure 1. Metallothionein levels in human liverand kidney for different age groups. Metallothionein was estimated by
Cd-saturation method; details ofthedata are presented in Chung etal. (12).
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Table 1. Localization of metallothionein in human tumors.a
Organ Tumor
Adenoma
Follicular adenocarcinoma
Papillary adenocarcinoma
Seminoma
Embryonal carcinoma
Teratocarcinoma
Choriocarcinoma
Transitional cell carcinoma Urinary bladder
Salivarygland Pleomorphic adenoma
Adenoid cystic carcinoma
Adenocarcinoma
Colorectal Adenocarcinoma
Reference
Narteyetal. (17)
Chin etal. (20)
Kontazoglou etal. (19)
Bahnson et al. (18)
Chauvin etal. (21)
Haile-Miskel etal. (22)
Haile-Miskel etal. (22)
aArchival paraffin-embedded tissue sections fixed in formalin were stained formetallothionein using a specific polyclonal
antibodyand peroxidase-antiperoxidase method as described in detail byNarteyetal.(17).
to metallothionein in human fetal livers
(14 to 16 gestational weeks). There is no
detectable cadmium in any human tissue at
birth. In contrast to high hepatic metal-
lothionein levels in the fetus, the concen-
tration of metallothionein in the kidney is
low (Figure 1). The few samples analyzed
from newborn children and those under
the age of 20 showed low metallothionein
levels in both liver and kidney. The bind-
ing of zinc and copper to metallothionein
and its high expression in human fetal liver
suggests that metallothionein may serve as
a temporary reservoir for these metals dur-
ing fetal development. The requirement for
zinc is universal during mammalian growth
and development. Since DNA and RNA
polymerases and a number of other
enzymes may require zinc, the homeostatic
control ofthis metal is essential for catalysis
ofmetabolic processes, nucleic acid metab-
olism, and protein synthesis.
Similar to human fetal liver, a high
level of metallothionein was detected in
fetal and neonatal rat liver. In Sprague-
t ,loo1ii1uc
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Dawley rats, while metallothionein was
barely detectable in liver on day 15 of ges-
tation, a dramatic increase in hepatic met-
allothionein concentration was observed on
day 18 and it was continued until birth
(Figure 2). Both zinc and metallothionein
concentrations in liver were highest soon
after birth and they remained high until
about 14 days of age. As metallothionein
content in the liver increased on day 18 of
gestation, the Zn/metallothionein molar
ratio in liver decreased and then remained
constant at about 11 in late gestation and
neonatal periods. The results suggest that
about 65 to 70% of total zinc pool in the
rat liver during this period is bound to
metallothionein. The high hepatic concen-
tration ofboth zinc and metallothionein in
newborn rats decreased at a linear logarith-
mic rate as the pups grew older and
attained near adult levels on weaning
(9,11,13). Developmentally regulated
expression ofmetallothionein also has been
studied in cell culture using embryonal car-
cinoma cells induced to differentiate to
primitive visceral endoderm by retinoic
acid treatment (14). These results suggest
that the increased synthesis of metallo-
thionein in hepatocytes during fetal life
may be due to the high requirement for
essential metals such as zinc, which is nec-
essary for various metabolic processes in
embryonic development, cellular differenti-
ation, and cell proliferation.
In addition to the high expression of
metallothionein in mammalian liver during
early development, there is a marked differ-
ence in the cellular localization ofmetallo-
thionein as determined by immuno-
histochemical staining with a specific met-
allothionein antibody. We have demon-
strated that although metallothionein is
localized mainly in the cytoplasm in adult
liver (Figure 3), it can also be detected in
hepatocyte nuclei (Figure 4) in human fetal
liver and in fetal and neonatal rat liver
(9,11,13,15,16). The high expression of
metallothionein and its mRNA in fetal rat
liver is dependent on the maternal zinc sta-
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Figure Hepatic zinc and metallothionein levels in rats
during perinatal and postnatal development. The data are
adapted from Panemangalore et al. (9) and Templeton et
al.(13).
Figure 3. Cellular localization of metallothionein in adult human liver. Metallothionein was localized by immunohisto-
chemistry using a specific polyclonal antibody and peroxidase-antiperoxidase method as described in Nartey et al. (15).
The staining formetallothionein was mainly inthe cytoplasm and mostofthe nuclei did notstain. The cytoplasmic stain-
ing is indicated by no counterstain.
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Table2. Distribution of metallothionein staining and clinical staging ofgerm cell tumors.
Tumor
Seminoma (n= 10)
Metallothionein staining
oa
++
Stage
11
6
0
0
0
Ill
1
0
0
0
2
0
0
Nonseminoma (n =22)
Metallothionein staining
0
++
IIA
2
0
6
2
IIB
0
0
0
3
III
0
0
0
3
1
3
0
2
0o no metallothionein staining; +, weak; ++, moderate; i-s-I, strong staining. Nonseminomas are embryonal carcinoma ter-
atocarcinoma, and choriocarcinoma. Adapted from Chin et. al.(20).
tus (16). The hepatic metallothionein level
in newborn rats is markedly decreased
when the pregnant rats are fed a zinc-defi-
cient diet at late gestation period (11,16).
The neonates born from zinc-deficient
mothers were able to induce metallo-
thionein synthesis following injection of
zinc salts, suggesting that the accumulation
of zinc in the fetal liver during late gesta-
tion plays an important role in the induc-
tion ofmetallothionein. Although there are
distinct differences in the nuclear-cytoplas-
mic presence of endogenous metalloth-
ionein in hepatocytes depending on the
developmental stage, the significance of
these changes in intracellular localization of
metallothionein is not yet understood.
These changes in developmental and intra-
cellular localization profiles and gene
expression of metallothionein suggest that
metallothionein could be considered an
oncodevelopmental gene product.
There is increasing evidence that cer-
tain proteins such as a-fetoproteins whose
normal expressions are restricted to the
embryonal and fetal periods, are frequently
reexpressed in certain tumors. The re-
expression of the proteins in tumors may
be closely related to cellular differentiation
and some ofthe proteins are used as tumor
markers in certain neoplasia. In a report
published in 1987, we used immunohisto-
chemical localization to demonstrate the
distinct presence of metallothionein in 31
of 34 human thyroid tumors in archival
paraffin-embedded tissue samples; less than
20% of normal thyroid glands showed a
diffused distribution of metallothionein
(17). The positive staining for metallo-
thionein was present in both nucleus and
cytoplasm of thyroid adenomas and
carcinomas. In subsequent studies (Table
1), we have demonstrated the presence of
metallothionein in various human tumors
including transitional cell carcinoma ofuri-
nary bladder (18), testicular embryonal
carcinoma (19), other types of testicular
tumors (20), pleomorphic adenoma and
adenoid cystic carcinoma of salivary gland
(21), and adenocarcinoma of breast and
colorectum (22). These studies show that
metallothionein is expressed in both benign
adenomas and malignant carcinomas and
can be detected in nucleus and cytoplasm
of tumor cells. However, the staining for
metallothionein is not universal to all
tumor growth; but it may depend on vari-
ous factors that may be related to the type
oftumor, its cellular origin, morphological
heterogeneity, or stage of growth. The
development ofsubpopulations ofmicrore-
gions of heterogeneous cells with a variety
ofgrowth and functional properties within
tumors (23) creates additional obstacles to
study the role of expression ofcertain spe-
cific proteins such as metallothionein.
The immunohistochemical staining of
metallothionein in various tumors showed
its presence mainly in epithelial cells, espe-
cially on the proliferating edge of the
tumor (19). There was a distinct difference
between metallothionein staining in semi-
nomas and nonseminomas in human tes-
ticular tumors (Table 2). Pure seminomas
showed little or no staining for metalloth-
ionein, irrespective of clinical stage, while
nonseminomas stained heavily for metal-
lothionein, especially in the more advanced
stages (20). In general, seminomas are well-
differentiated tumors and are very sensitive
to both radiation and chemotherapy (24).
However, it is unknown whether there is
any direct relationship between the
radiosensitivity or chemosensitivity of
seminomas and the absence of metalloth-
ionein or differences in subcellular localiza-
tion. The staining of metallothionein in
pleomorphic adenomas and adenoid cystic
carcinomas of human salivary gland
showed its presence mainly in myoepithe-
lial cells with intense staining in the prolif-
erating edge (21). These tumors are known
to be relatively radioresistant. The differ-
ences in metallothionein localization in
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Figure 4. Cellular localization of metallothionein in human fetal liver. Fourteen-week-old fetal liver was stained with.a
specific antibody to metallothionein as described by Nartey et. al. (15). Cytoplasmic (closed arrows) and nuclear (open
arrow)staining formetallothionein are shown. No counterstain.
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embryonal carcinoma cells are closely
related to their well-defined histomorpho-
logical patterns (19). This study showed
that tumors with a typical glandular-papil-
lary pattern, corresponding to the epiblastic
or ectodermal pattern were strongly posi-
tive for metallothionein, while tumors
growing in solid masses, designated embry-
oblastic, were negative or weakly positive
for metallothionein at the periphery. These
results suggest that the variability ofmetal-
lothionein staining in human tumors may
reflect their morphological heterogeneity,
which may also correlate with the degree of
differentiation and maturation of the
tumor cells. Thus, the tumors with solid
pattern, which resembles the better-differ-
entiated seminomas, may have less cellular
metabolic activity and less requirement for
zinc than other morphological patterns of
embryonal carcinomas, which therefore
may have little metallothionein. These dif-
ferences in growth patterns within the
tumors may explain the different expres-
sion ofmetallothionein in various tumors.
The significance ofthe presence ofmet-
allothionein in the nucleus of hepatocytes
during development (9,15) or partial hepa-
tectomy (25) and also in certain tumor
cells (17-22) is not yet understood but
may be related to the interactions ofmetal
ions like zinc with various nuclear con-
stituents during the cell cycle. The metals
that bind to metallothionein can also bind
to histones, nucleolar RNA, and nuclear
acidic proteins, and may modify gene
expression and phosphorylatin of regula-
tory proteins. The presence of metallo-
thionein in the cell nucleus can effectively
donate zinc to several enzymes or chelate
zinc from transcription factors such as zinc
finger proteins (26). These protein-metal
interactions in the nucleus can modifyvari-
ous cellular processes, including gene tran-
scription and enzymatic activity.
The subcellular localization of metal-
lothionein in primary cultured adult rat
hepatocytes stimulated by epidermal
growth factor and insulin showed that
there was a transient presence of metallo-
thionein in the nucleus during the early S-
phase of cell cycle (27). Metallothionein
also has been localized in hair follicles in
normal skin and in the basal layer ofhyper-
plastic epidermis, indicating its association
with proliferation of epidermal ker-
atinocytes (28). In a recent DNA flow
cytometry study (22), we demonstrated the
localization of metallothionein in the
nucleus ofboth diploid and aneuploid cells
during the S-phase and not during G-1
phase of cell cycle of adenocarcinomas of
breast and colon. In a previous study (9),
the attempts to demonstrate the presence
ofmetallothionein in cell nuclei isolated by
biochemical techniques from newborn rats
were not successful because ofthe leaching
out of low-molecular-weight metallo-
thionein through the nuclear pores. In the
DNA flow cytometry study, the cell nuclei
were isolated from archival tumor tissue,
and fixed in formalin by the method of
Hedley et al. (29). The polymerized form of
metailothionein in the nucleus of forma-
lin-fixed tissues cannot leach out, and
therfore intact nuclei containing metalloth-
ionein can be isolated. Thus the physiolog-
ical role of metallothionein is closely
related to its nuclear presence in the prolif-
erating phase ofthe cell cycle, where metal-
lothionein may have a significant role to
supply zinc to enzymes involved in the syn-
thesis of nucleic acid and protein or to
chelate zinc from transcriptional factors.
It is well established that the cell kinetic
status of malignant tumors has prognostic
implications (30,31). An active tumor
growth implies cell proliferation and loss of
differentiation, which may depend on the
growth fraction, cell cycle time, and cell
loss. The abnormal ploidy and elevated
proliferative activity are associated with
poor clinical outcome in locoregional
breast, non-small cell lung, ovarian, and
colorectal cancers. Therefore, for diagnostic
and therapeutic purposes, it is ofinterest to
characterize tumors with expression ofdif-
ferent antigens related to the cell cycle. The
results ofpreliminary DNA flow cytometry
studies of breast and colon carcinoma to
localize metallothionein in cellular nucleus
suggest that it may provide a good indica-
tion of the proliferating fraction of cell-
cycle in tumors. Further studies are
required to demonstrate whether metal-
lothionein labeling index in flow cytometry
can be used for prognosis in histopatholog-
ical evaluation ofepithelial malignancies.
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